![](https://www.pymnts.com/wp-content/uploads/2019/12/shutterstock_154973519-e1621847906771.jpg)
Pharmaceutical giant Bristol Myers Squibb has agreed to pay 10 million shekels ($2.7 million) to settle a potential antitrust case in Israel. This settlement pertains to allegations that the company obstructed the creation of a generic version of its anti-cancer drug, Imnovid. The Israel Competition Authority announced this decision on Monday.
The anti-cancer drug Imnovid, distributed in Israel by Neopharm Scientific, is vital for treating multiple myeloma and AIDS-related Kaposi sarcoma. The controversy began when Bristol Myers Squibb and Neopharm Scientific declined a request from KS Kim International for samples needed to develop a generic version of the drug. Although the samples were eventually provided after a five-month delay, the Israel Competition Authority contended that this postponement hindered competition for a crucial medication.
Jonathan Cwikel, deputy legal counsel for civil and administrative affairs at the Israel Competition Authority, emphasized the broader message this settlement sends. “We want to send a message to companies that have a dominant position in the market that they cannot act in a manner that is likely to reduce competition,” Cwikel told Reuters.
The Israel Competition Authority initially planned to fine Neopharm 64 million shekels and an unnamed company executive 600,000 shekels. However, before a similar action could be taken against Bristol Myers Squibb, the company proposed a settlement, as explained by Cwikel.
Featured News
White & Case Appoints Rebecca Farrington as Co-Head of Global Antitrust Practice
Jul 1, 2024 by
CPI
Boeing Announces $8.3 Billion Definitive Agreement to Acquire Spirit AeroSystems
Jul 1, 2024 by
CPI
Bristol Myers Squibb Settles Israel Antitrust Case for $2.7 Million
Jul 1, 2024 by
CPI
French Antitrust Regulator to Charge Nvidia Over Alleged Anti-Competitive Practices
Jul 1, 2024 by
CPI
Antitrust Authority Fines Italian Soccer Federation €4.03 Million
Jul 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Private Equity Roll-Up Schemes
Jun 28, 2024 by
CPI
The FTC’s Focus on Private Equity is Warranted
Jun 28, 2024 by
CPI
Unraveling the Roll-Up: Private Equity’s Misunderstood Investment Strategy
Jun 28, 2024 by
CPI
Antitrust Focus on Private Equity Funds and Serial Acquisitions
Jun 28, 2024 by
CPI
Private Equity Roll-Ups Amidst Heightened Antitrust Enforcement
Jun 28, 2024 by
CPI